One analyst did not like what he saw out of Netflix earnings

Investing

Chesnot | Getty Images

Despite the big surge in the stock, Macquarie Research downgraded its rating of Netflix to neutral from outperform on Thursday, saying the streaming service’s latest quarterly results were “comforting, but competition is coming.”

“We think it will be hard for Netflix to grow much more in the US, and we suspect pricing power is limited. Content costs continue to rise and marketing demands will remain high, and the turn to positive [free cash flow] will take many years, while another debt raise is forthcoming,” Macquarie analysts Tim Nollen and Jordan Boretz wrote in a note to investors.

Before reporting third-quarter results on Wednesday, shares of Netflix were down 25% from its all-time high as fears mount about the launch of rival services from the likes of Disney and Apple. Netflix’ third-quarter earnings handily beat Wall Street’s expectations, with revenue coming in nearly on track as well. But Neflix delivered much lower U.S. subscriber growth than anticipated, even as international subscribers growth remained strong.

“In some ways Netflix has defied the naysayers in Q3, coming close enough to guidance and delivering impressive revenue and earnings growth. We still think its opportunity is excellent, especially internationally where sub adds should continue to step up. But it’s hard to deny the US is maturing,” Macquarie said.

Netflix stock rose 8% in premarket trading from its previous close of $286.28 a share. Macquarie also lowered its price target on Netflix to $325 a share from $375 a share.

– CNBC’s Michael Bloom contributed to this report.

Articles You May Like

How the ‘vibecession,’ global economic uncertainty are influencing investors this election year
Carvana raises 2024 earnings guidance after topping Wall Street’s Q3 expectations
Here’s how to leverage higher income limits for the 0% capital gains bracket
Trump says he will give RFK Jr. a major health role if he wins the White House. Here’s what that means for patients, drugmakers
$2 billion marina development aims to turn Fort Lauderdale into ‘mini Monaco’

Leave a Reply

Your email address will not be published. Required fields are marked *